JP2005524387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005524387A5 JP2005524387A5 JP2003544075A JP2003544075A JP2005524387A5 JP 2005524387 A5 JP2005524387 A5 JP 2005524387A5 JP 2003544075 A JP2003544075 A JP 2003544075A JP 2003544075 A JP2003544075 A JP 2003544075A JP 2005524387 A5 JP2005524387 A5 JP 2005524387A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- sequence selected
- polynucleotide
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 74
- 229920001184 polypeptide Polymers 0.000 claims 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims 68
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 29
- 108091033319 polynucleotide Proteins 0.000 claims 28
- 239000002157 polynucleotide Substances 0.000 claims 28
- 102000040430 polynucleotide Human genes 0.000 claims 28
- 239000012634 fragment Substances 0.000 claims 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 241000589516 Pseudomonas Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33122101P | 2001-11-13 | 2001-11-13 | |
| PCT/CA2002/001740 WO2003042240A2 (en) | 2001-11-13 | 2002-11-13 | Polypeptides of pseudomonas aeruginosa |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010016179A Division JP5636194B2 (ja) | 2001-11-13 | 2010-01-28 | 緑膿菌のポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005524387A JP2005524387A (ja) | 2005-08-18 |
| JP2005524387A5 true JP2005524387A5 (https=) | 2006-01-05 |
| JP4481646B2 JP4481646B2 (ja) | 2010-06-16 |
Family
ID=23293077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003544075A Expired - Fee Related JP4481646B2 (ja) | 2001-11-13 | 2002-11-13 | 緑膿菌のポリペプチド |
| JP2010016179A Expired - Fee Related JP5636194B2 (ja) | 2001-11-13 | 2010-01-28 | 緑膿菌のポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010016179A Expired - Fee Related JP5636194B2 (ja) | 2001-11-13 | 2010-01-28 | 緑膿菌のポリペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7459165B2 (https=) |
| EP (1) | EP1458752A2 (https=) |
| JP (2) | JP4481646B2 (https=) |
| AU (2) | AU2002340683C1 (https=) |
| CA (2) | CA2466474C (https=) |
| ES (1) | ES2431318T3 (https=) |
| WO (1) | WO2003042240A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2571673A1 (en) * | 2004-06-28 | 2006-01-05 | Proteome Systems Intellectual Property Pty Ltd | Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor |
| EP1845944A4 (en) * | 2005-02-08 | 2011-07-27 | Id Biomedical Corp Of Quebec C O B As Glaxosmithkline Biolog North America | PHARMACEUTICAL COMPOSITIONS |
| EP1868651A4 (en) | 2005-04-12 | 2010-10-06 | Univ Duke | METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS |
| US7781166B2 (en) * | 2006-03-31 | 2010-08-24 | Marshall University Research Corporation | Methods of detecting and controlling mucoid pseudomonas biofilm production |
| MX343607B (es) * | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
| MX2013007146A (es) * | 2010-12-23 | 2013-11-01 | Intercell Austria Ag | Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. |
| WO2015048635A1 (en) | 2013-09-27 | 2015-04-02 | Duke University | Mper-liposome conjugates and uses thereof |
| WO2016105536A2 (en) | 2014-12-23 | 2016-06-30 | University Of Maryland, Baltimore | Muc1 decoy peptides for treatment and prevention of bacterial infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| DE3718591A1 (de) * | 1987-06-03 | 1988-12-15 | Behringwerke Ag | Aeusseres membranprotein f von pseudomonas aeruginosa |
| US5591838A (en) * | 1993-02-12 | 1997-01-07 | Board Of Regents, The University Of Texas System | Detection of conversion to mucoidy in pseudomonas aeruginosa infecting cystic fibrosis patients |
| ATE190657T1 (de) | 1994-12-16 | 2000-04-15 | Chiron Behring Gmbh & Co | Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| JP2002513802A (ja) * | 1998-05-06 | 2002-05-14 | ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ | Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａのためのワクチン |
| GB9915419D0 (en) * | 1999-07-01 | 1999-09-01 | Cortecs Uk Ltd | Antigens |
| GB9928676D0 (en) * | 1999-12-03 | 2000-02-02 | Provalis Uk Ltd | Pseudomonas aeruginosa antigens |
| WO2002064161A2 (en) * | 2001-01-26 | 2002-08-22 | Mcw Research Foundation, Inc. | Method and compositions for immunization with the pseudomonas v antigen |
-
2002
- 2002-11-13 AU AU2002340683A patent/AU2002340683C1/en not_active Ceased
- 2002-11-13 US US10/495,455 patent/US7459165B2/en not_active Expired - Fee Related
- 2002-11-13 CA CA2466474A patent/CA2466474C/en not_active Expired - Fee Related
- 2002-11-13 ES ES06022429T patent/ES2431318T3/es not_active Expired - Lifetime
- 2002-11-13 WO PCT/CA2002/001740 patent/WO2003042240A2/en not_active Ceased
- 2002-11-13 JP JP2003544075A patent/JP4481646B2/ja not_active Expired - Fee Related
- 2002-11-13 CA CA2784450A patent/CA2784450C/en not_active Expired - Fee Related
- 2002-11-13 EP EP02774222A patent/EP1458752A2/en not_active Withdrawn
-
2009
- 2009-06-23 AU AU2009202507A patent/AU2009202507C1/en not_active Ceased
-
2010
- 2010-01-28 JP JP2010016179A patent/JP5636194B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006525330A5 (https=) | ||
| RO117924B1 (ro) | Polipeptidă de suprafaţă a bacteriei neisseria meningitidis 608b, rezistentă la proteinaza k, polinucleotidă care o codifică şi compoziţie farmaceutică cu aceasta | |
| AU6576800A (en) | Use of a polypeptide for detecting, preventing or treating pathological condition associated with a degenerative, neurological or autoimmune disease | |
| CA2356836A1 (en) | Novel streptococcus antigens | |
| JP2002502589A5 (https=) | ||
| JP2002521055A5 (https=) | ||
| EP2287189A1 (en) | Small Streptococcus pyogenes antigens and their use | |
| JP2002502600A (ja) | ヒトセリンプロテアーゼおよびセルピンポリペプチド | |
| JP2005524387A5 (https=) | ||
| JP2002517193A5 (https=) | ||
| JP2003511078A (ja) | 複数のエピトープと融合した組換えタンパク質の精製 | |
| CA2413576A1 (en) | Streptococcus pyogenes antigens | |
| EP0567470B1 (en) | Pseudomonas peptide composition and method for producing the same | |
| JP2005535287A5 (https=) | ||
| CA2475821A1 (en) | Group b streptococcus antigens | |
| CA2466474A1 (en) | Compositions comprising spa-1, spa-2 and spa-3, polypeptides and related uses | |
| JP2001515720A (ja) | β−デフェンシン | |
| JP2004531235A5 (https=) | ||
| KR20010005701A (ko) | 모틸린 상동체 | |
| CA2438921A1 (en) | Streptococcus pyogenes polypeptides and corresponding dna fragments | |
| CN110257405B (zh) | 牛支原体乙醇脱氢酶基因及其编码蛋白与应用 | |
| JP2003507029A5 (https=) | ||
| CA2432525A1 (en) | Streptococcus pyogenes antigens and corresponding dna fragments | |
| JP2005501534A5 (https=) | ||
| CA2247072A1 (en) | Bacterial elastin binding protein, nucleic acid sequence encoding same and diagnostic and therapeutic methods of use thereof |